ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.81
+0.18 (2.09%)
At close: Oct 28, 2026, 4:00 PM EDT
8.79
-0.02 (-0.23%)
Pre-market: Oct 29, 2026, 5:26 AM EDT

ImmunityBio Stock Forecast

Stock Price Forecast

According to 4 analysts polled by S&P Global, ImmunityBio stock has a consensus rating of "Strong Buy" and an average price target of $14.25. The average 1-year stock price forecast is 61.75% higher than the current stock price, while the lowest is $12 (+36.21%) and the highest is $16 (+81.61%).

Price Target: $14.25 (+61.75%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$12$14.25$14.5$16
Change+36.21%+61.75%+64.59%+81.61%

Analyst Ratings

The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingMay '26Jun '26Jul '26Aug '26Sep '26Oct '26
Strong Buy223333
Buy111111
Hold000000
Sell000000
Strong Sell000000
Total334444

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$15
BuyReiterates$15+70.26%Oct 15, 2026
BTIG
BTIG
Buy
Maintains
$12
BuyMaintains$12+36.21%Oct 15, 2026
Jefferies
Jefferies
Buy
Maintains
$12 → $14
BuyMaintains$12 → $14+58.91%Oct 14, 2026
Piper Sandler
Piper Sandler
Buy
Maintains
$12 → $16
BuyMaintains$12 → $16+81.61%Oct 14, 2026

Financial Forecast

Revenue This Year
226.56M
from 113.29M
Increased by 99.98%
Revenue Next Year
471.90M
from 226.56M
Increased by 108.29%
EPS This Year
-0.92
from -0.38
EPS Next Year
-0.07
from -0.92
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
934.00K240.00K622.00K14.75M113.29M226.56M
Revenue Growth
54.38%-74.30%159.17%2,270.58%668.32%99.98%
Gross Profit
934.00K240.00K622.00K14.75M112.54M224.07M
Gross Margin
100.00%100.00%100.00%100.00%99.34%98.90%
Operating Income
-317.42M-350.67M-361.36M-344.18M-256.03M-237.17M
Net Income
-346.79M-416.57M-583.20M-413.56M-351.40M-1.00B
EPS
-----0.38-0.92
Free Cash Flow
-----308.42M-462.57M
No. Analysts
-----4
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High254.1M
Avg226.6M
Low213.2M

Revenue Growth

Revenue Growth202620272028
High
124.3%
Avg
100.0%
Low
88.2%

EPS Forecast

EPS202620272028
High-0.90
Avg-0.92
Low-0.93

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-